RBC Capital Markets adjusted their outlook on Morgan Stanley (NYSE:MS) shares, raising the price target from $122.00 to $142.00. The firm maintained a Sector Perform rating on the stock. The upgrade comes as Morgan Stanley's stock trades near its 52-week high of $136.

Automotive (NASDAQ: ORLY), increasing the price target from $1,286.00 to $1,416.00, while maintaining an Outperform rating on the company's shares. Currently trading at $1,263.87 and near its 52-week high,

RBC Capital analyst Brad Heffern maintained a Hold rating on UDR (UDR – Research Report) today and set a price target of $43.00. The company’s

Bank stocks have been on a post-election upswing, with the KBW Nasdaq Bank Index ( ^BKX) up 14% since Trump won the presidency. Morgan Stanley has notched a 17% gain. Investors have a dinner plate to choose from to explain the bullishness.

The CEO also said he is ‘bullish’ on the potential for stock sales, including initial public offerings in 2025.

In a report released today, James Edwardes Jones from RBC Capital maintained a Buy rating on Reckitt (RKT – Research Report), with a price

Morgan Stanley's profit more than doubled in the fourth quarter, fueled by a wave of dealmaking and stock sales that drove its revenue to a full-year record.

RBC Capital Markets analyst Maurice Choy identifies relative “safer havens” in the yield-heavy energy infrastructure sector, National Bank economist Warren Lovely noted the important fact that global interest in Canadian bonds remains high,

Daniel Fannon; Analyst; Jefferies & Company Inc. Gerard Cassidy; Analyst; RBC Capital Markets

Key stocks in the Dow Jones Industrial Average (DJIA), including McDonald’s, JPMorgan, and Goldman Sachs. Analyze ratings, profitability,..

The S&P 500 and Nasdaq each gained approximately 1.7% for the week, while the Dow rose 2.2%. The S&P 500 not only set intraday records but also achieved a new all-time closing high on Thursday.

Equities research analysts at Wedbush dropped their FY2024 EPS estimates for Biogen in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings per share of $16.